These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16421682)

  • 1. Effect of propofol on ropivacaine metabolism in human liver microsomes.
    Osaka Y; Inomata S; Tanaka E; Nakamura T; Honda K; Miyabe M; Toyooka H; Tanaka M
    J Anesth; 2006; 20(1):60-3. PubMed ID: 16421682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.
    Oda Y; Furuichi K; Tanaka K; Hiroi T; Imaoka S; Asada A; Fujimori M; Funae Y
    Anesthesiology; 1995 Jan; 82(1):214-20. PubMed ID: 7832304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro.
    Tanaka E; Nakamura T; Inomata S; Honda K
    Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):181-3. PubMed ID: 16445592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.
    Ekström G; Gunnarsson UB
    Drug Metab Dispos; 1996 Sep; 24(9):955-61. PubMed ID: 8886604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propofol inhibits lidocaine metabolism in human and rat liver microsomes.
    Inomata S; Nagashima A; Osaka Y; Kazama T; Tanaka E; Sato S; Toyooka H
    J Anesth; 2003; 17(4):246-50. PubMed ID: 14625712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine.
    Berggren S; Lennernäs P; Ekelund M; Weström B; Hoogstraate J; Lennernäs H
    J Pharm Pharmacol; 2003 Jul; 55(7):963-72. PubMed ID: 12906753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
    Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
    Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.
    Arlander E; Ekström G; Alm C; Carrillo JA; Bielenstein M; Böttiger Y; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Nov; 64(5):484-91. PubMed ID: 9834040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine.
    Jokinen MJ; Olkkola KT; Ahonen J; Neuvonen PJ
    Eur J Clin Pharmacol; 2003 Feb; 58(10):653-7. PubMed ID: 12610740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes.
    Lejus C; Fautrel A; Mallédant Y; Guillouzo A
    Biochem Pharmacol; 2002 Oct; 64(7):1151-6. PubMed ID: 12234619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propofol-induced cytochrome P450 inhibition: an in vitro and in vivo study in rats.
    Gemayel J; Géloën A; Mion F
    Life Sci; 2001 May; 68(26):2957-65. PubMed ID: 11411795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.
    Guns ES; Bullock PL; Reimer ML; Dixon R; Bally M; Mayer LD
    Eur J Drug Metab Pharmacokinet; 2001; 26(4):273-82. PubMed ID: 11808870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro.
    Tanaka E; Takano Y; Inomata S; Toyooka H; Honda K
    Eur J Clin Pharmacol; 2004 Oct; 60(8):565-8. PubMed ID: 15351923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 1.5% lidocaine and 0.5% ropivacaine epidural anesthesia combined with propofol general anesthesia guided by bispectral index.
    Xiang Y; Li YH
    J Zhejiang Univ Sci B; 2007 Jun; 8(6):428-34. PubMed ID: 17565514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
    Casabar RC; Wallace AD; Hodgson E; Rose RL
    Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.
    Lieu C; Shi J; Donat F; Van Horn R; Brian W; Newton J; Delbressine L; Vos R
    Clin Pharmacokinet; 2002; 41 Suppl 2():19-26. PubMed ID: 12383041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of the in vitro interaction between lidocaine and premedications using human liver microsomes.
    Nagashima A; Tanaka E; Inomata S; Honda K; Misawa S
    J Clin Pharm Ther; 2005 Apr; 30(2):185-8. PubMed ID: 15811173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
    Brandes LJ; Queen GM; LaBella FS
    Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic interactions of magnolol with cytochrome P450 enzymes: uncompetitive inhibition of CYP1A and competitive inhibition of CYP2C.
    Kim SB; Kang HE; Cho HJ; Kim YS; Chung SJ; Yoon IS; Kim DD
    Drug Dev Ind Pharm; 2016; 42(2):263-9. PubMed ID: 26133083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.